CY1114315T1 - Εμβολιασμος γριπης με αγωγη πολλαπλων δοσεων με περιορισμενα εκδοχα - Google Patents

Εμβολιασμος γριπης με αγωγη πολλαπλων δοσεων με περιορισμενα εκδοχα

Info

Publication number
CY1114315T1
CY1114315T1 CY20131100167T CY131100167T CY1114315T1 CY 1114315 T1 CY1114315 T1 CY 1114315T1 CY 20131100167 T CY20131100167 T CY 20131100167T CY 131100167 T CY131100167 T CY 131100167T CY 1114315 T1 CY1114315 T1 CY 1114315T1
Authority
CY
Cyprus
Prior art keywords
vaccination
excipients
limited
multiple dosage
dosage influenza
Prior art date
Application number
CY20131100167T
Other languages
Greek (el)
English (en)
Inventor
Giudice Giuseppe Del
Riccardo Manetti
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38832174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1114315(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1114315T1 publication Critical patent/CY1114315T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CY20131100167T 2006-06-15 2013-02-25 Εμβολιασμος γριπης με αγωγη πολλαπλων δοσεων με περιορισμενα εκδοχα CY1114315T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81466506P 2006-06-15 2006-06-15
EP07804945A EP2032163B1 (en) 2006-06-15 2007-06-15 Adjuvant-sparing multi-dose influenza vaccination regimen

Publications (1)

Publication Number Publication Date
CY1114315T1 true CY1114315T1 (el) 2016-08-31

Family

ID=38832174

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100167T CY1114315T1 (el) 2006-06-15 2013-02-25 Εμβολιασμος γριπης με αγωγη πολλαπλων δοσεων με περιορισμενα εκδοχα

Country Status (17)

Country Link
US (3) US20090220545A1 (https=)
EP (1) EP2032163B1 (https=)
JP (2) JP5566687B2 (https=)
KR (1) KR20090016704A (https=)
CN (1) CN101500603A (https=)
AU (1) AU2007258874B2 (https=)
BR (1) BRPI0713150A8 (https=)
CA (1) CA2657989A1 (https=)
CY (1) CY1114315T1 (https=)
DK (1) DK2032163T3 (https=)
EA (1) EA017441B1 (https=)
ES (1) ES2401484T3 (https=)
PL (1) PL2032163T3 (https=)
PT (1) PT2032163E (https=)
SI (1) SI2032163T1 (https=)
WO (1) WO2007144772A2 (https=)
ZA (1) ZA200810582B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
CA2628152C (en) * 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
JP5518041B2 (ja) * 2008-03-18 2014-06-11 ノバルティス アーゲー インフルエンザウイルスワクチン抗原の調製における改良
GB0905570D0 (en) * 2009-03-31 2009-05-13 Novartis Ag Combined vaccines
EP3173097A3 (en) 2009-02-10 2017-07-12 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
KR101176305B1 (ko) * 2009-10-14 2012-08-23 웅진코웨이주식회사 붉나무 추출물을 포함하는 인플루엔자 바이러스 감염의 예방용 조성물, 상기 조성물을 포함하는 기상필터 및 상기 필터를 포함하는 공기청정기
KR101153630B1 (ko) * 2009-10-16 2012-06-18 웅진코웨이주식회사 타닌산을 포함하는 인플루엔자 바이러스 감염의 예방용 조성물, 상기 조성물을 포함하는 기상필터 및 상기 필터를 포함하는 공기청정기
US20110126501A1 (en) 2009-10-16 2011-06-02 Woongjin Coway Co., Ltd. Composition for prevention of influenza viral infection comprising tannic acid, air filter comprising the same and air cleaning device comprising the filter
WO2011102873A1 (en) * 2010-02-21 2011-08-25 Innovative Bottles, Llc Biodegradable pharmacy container and safety cap
EP2525815B1 (en) * 2010-01-24 2015-02-25 Novartis AG Irradiated biodegradable polymer microparticles
US8852157B2 (en) 2010-02-21 2014-10-07 Innovative Bottles, Llc Disposable items made from bioplastic resins
PL2569007T3 (pl) * 2010-05-11 2016-04-29 Intervet Int Bv Szczepionka przeciwko Mycoplasma Hyopneumoniae, odpowiednia do podawania w obecności przeciwciał pochodzących od matki
WO2012117377A1 (en) * 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
WO2016011343A1 (en) 2014-07-17 2016-01-21 The Trustees Of The University Of Pennsylvania Her3 peptides and dendritic cell vaccines
WO2016068333A1 (ja) * 2014-10-30 2016-05-06 中外製薬株式会社 シリンジキャップを具備した、針付プレフィルドシリンジ製剤
US10406290B2 (en) 2015-02-03 2019-09-10 Merz Pharma Gmbh & Co. Kgaa Botulinum toxin prefilled plastic syringe
US11013795B2 (en) 2015-06-26 2021-05-25 Seqirus UK Limited Antigenically matched influenza vaccines
CA2992925A1 (en) * 2015-07-17 2017-01-26 The Trustees Of The University Of Pennsylvania Identification of immunogenic mhc class ii peptides for immune-based therapy
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
WO2019121513A1 (en) 2017-12-18 2019-06-27 Intervet International B.V. Swine influenza a virus vaccine
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
EP3921413A1 (en) 2019-02-08 2021-12-15 Wisconsin Alumni Research Foundation (WARF) Humanized cell line
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
JP2023511444A (ja) 2020-01-24 2023-03-17 ウィスコンシン アルムニ リサーチ ファンデイション 安定化されたｎａを有する組換えインフルエンザウイルス
WO2021195410A1 (en) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990001947A1 (en) 1988-08-25 1990-03-08 The Liposome Company, Inc. Affinity associated vaccine
AU631377B2 (en) * 1988-08-25 1992-11-26 Liposome Company, Inc., The Affinity associated vaccine
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
DE10012370A1 (de) * 2000-03-14 2001-09-27 Chiron Behring Gmbh & Co Adjuvans für Vakzinen
DK1635863T3 (da) * 2003-06-17 2010-11-22 Mannkind Corp Sammensætninger til udløsning, forbedring og opretholdelse af immunresponser mod MHC-klasse-i-begrænsede epitoper til profylaktiske eller terapeutiske formål
JP5600375B2 (ja) * 2004-03-09 2014-10-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド インフルエンザウイルスワクチン
AR054020A1 (es) 2005-03-23 2007-05-30 Glaxosmithkline Biolog Sa Nuevo uso
AU2006310338A1 (en) * 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Adminstration routes for priming/boosting with influenza vaccines
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
MX2009000660A (es) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.

Also Published As

Publication number Publication date
CA2657989A1 (en) 2007-12-21
ZA200810582B (en) 2009-09-30
EA200970013A1 (ru) 2009-06-30
JP5566687B2 (ja) 2014-08-06
WO2007144772A3 (en) 2008-03-27
KR20090016704A (ko) 2009-02-17
US9901630B2 (en) 2018-02-27
US20090220545A1 (en) 2009-09-03
US20120039934A1 (en) 2012-02-16
US20140370053A1 (en) 2014-12-18
EP2032163A2 (en) 2009-03-11
EP2032163B1 (en) 2013-01-23
CN101500603A (zh) 2009-08-05
DK2032163T3 (da) 2013-03-25
SI2032163T1 (sl) 2013-05-31
EA017441B1 (ru) 2012-12-28
US8808686B2 (en) 2014-08-19
AU2007258874B2 (en) 2013-11-14
HK1129205A1 (en) 2009-11-20
JP2009539965A (ja) 2009-11-19
JP5981951B2 (ja) 2016-08-31
WO2007144772A2 (en) 2007-12-21
JP2014098038A (ja) 2014-05-29
BRPI0713150A2 (pt) 2012-03-27
AU2007258874A1 (en) 2007-12-21
PL2032163T3 (pl) 2013-06-28
ES2401484T3 (es) 2013-04-22
BRPI0713150A8 (pt) 2017-08-22
PT2032163E (pt) 2013-04-11

Similar Documents

Publication Publication Date Title
CY1114315T1 (el) Εμβολιασμος γριπης με αγωγη πολλαπλων δοσεων με περιορισμενα εκδοχα
CY1118372T1 (el) Νεα μεθοδος και συνθεσεις
CY1120347T1 (el) Εμβολιο ιου ερπητα ζωστηρα
NZ585674A (en) Vaccination with multiple clades of h5 influenza a virus
CL2021003019S1 (es) Porción de dispositivo para administración de dosis. (divisional solicitud 200003174)
CY1111553T1 (el) Φαρμακοτεχνικες μορφες εμβολιου γριπης για ενδοδερμικη χορηγηση
AR032597A1 (es) Uso de antigenos del virus de la gripe inactivado, en la preparacion de vacunas de una sola dosis intranasal; metodo para la profilaxis de enfermedades o de infecciones gripales en pacientes; equipos que comprenden dichas vacunas en dosis unicas y metodo para fabricar vacunas para la gripe para apli
EA201171032A1 (ru) Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
WO2008096831A1 (ja) 癌の治療剤
BRPI0716518B8 (pt) vacina de ipv e uso da mesma
CR11307A (es) Vacunas
DE60142615D1 (de) Epitop-synchronisierung in antigen präsentierenden zellen
CY1112634T1 (el) Εμβολια κατα της ελονοσιας που βασιζονται σε ανασυνδυασμενο ιο
CY1107302T1 (el) Χρηση ρεσβερατρολης για την παρασκευη ενος φαρμακου που ειναι χρησιμο για τη θεραπεια λοιμωξεων απο τον ιο της γριπης
MX386606B (es) El uso de una vacuna para la prevención de diarrea epidémica porcina.
NO20065480L (no) Vaksiner.
AR119159A1 (es) Tratamientos de angioedema
CL2025000520A1 (es) Paradigma de tratamiento para una terapia con anticuerpos anti-cd19.
MX2013009757A (es) Metodo de seleccion rapida para vih variantes gp-120.
BR112019009029A2 (pt) anticorpos anti-bag3 em combinação com inibidores do ponto de verificação imune para uso terapeutico
EA201170569A1 (ru) Лекарственное средство для повышения дозы противоаллергической вакцины
MX2022007305A (es) Mejoras en la administracion sin aguja.
BR112022009421A2 (pt) Regimes de dosagem para vacinas
AR052392A1 (es) Mutantes de la proteina n del virus del sindrome reproductor y respiratorio de los porcinos
WO2006062637A3 (en) Influenza vaccination